Sanjeev Satyal
Corporate Officer/Principal bei MONTEREY INNOVATION ACQUISITION CORP.
Profil
Sanjeev Satyal is currently an Advisor at Monterey Innovation Acquisition Corp.
He previously worked as the CEO and Vice President of Research & Development at pH Pharma Co., Ltd.
from 2018 to 2021.
Before that, he held positions as the Director of Cancer Biology at OncoMed Pharmaceuticals, Inc., Director of Research at StemPar Sciences, Inc., and Vice President of Biology at Stemguard Therapeutics, Inc. Dr. Satyal holds a doctorate degree from Northwestern University, a graduate degree from the University of Pune, and an undergraduate degree from St. Xavier's College.
Aktive Positionen von Sanjeev Satyal
| Unternehmen | Position | Beginn |
|---|---|---|
| MONTEREY INNOVATION ACQUISITION CORP. | Corporate Officer/Principal | 09.03.2023 |
Ehemalige bekannte Positionen von Sanjeev Satyal
| Unternehmen | Position | Ende |
|---|---|---|
pH Pharma Co., Ltd.
 pH Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology pH Pharma Co. Ltd. engages in the developing and manufacturing of bio-pharmaceuticals. Its products include php-303, php-201, ab-101, nuvesse, alpine and torpedo products. The company was founded by Ho Young Huh on September 22, 2015 and is headquartered in Seoul, South Korea. | Chief Executive Officer | 01.02.2021 |
| ONCOMED PHARMACEUTICALS INC | Corporate Officer/Principal | - |
StemPar Sciences, Inc.
 StemPar Sciences, Inc. Medical/Nursing ServicesHealth Services StemPar Sciences, Inc. develops cancer drugs treatments. It provides cancer drugs that attack solid tumors by simultaneously disrupting their source of energy and their ability to repair chemotherapy/radiation induced DNA damage. The company was founded by Hoyoung Huh and Mircea Florin Mihaescu in 2012 and is headquartered in Mill Valley, CA. | Chief Tech/Sci/R&D Officer | - |
| Stemguard Therapeutics, Inc. | Corporate Officer/Principal | - |
Ausbildung von Sanjeev Satyal
| Northwestern University | Doctorate Degree |
| University of Pune | Graduate Degree |
| St. Xavier's College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
OncoMed Pharmaceuticals, Inc.
 OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
StemPar Sciences, Inc.
StemPar Sciences, Inc. Medical/Nursing ServicesHealth Services StemPar Sciences, Inc. develops cancer drugs treatments. It provides cancer drugs that attack solid tumors by simultaneously disrupting their source of energy and their ability to repair chemotherapy/radiation induced DNA damage. The company was founded by Hoyoung Huh and Mircea Florin Mihaescu in 2012 and is headquartered in Mill Valley, CA. | Health Services |
pH Pharma Co., Ltd.
pH Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology pH Pharma Co. Ltd. engages in the developing and manufacturing of bio-pharmaceuticals. Its products include php-303, php-201, ab-101, nuvesse, alpine and torpedo products. The company was founded by Ho Young Huh on September 22, 2015 and is headquartered in Seoul, South Korea. | Health Technology |
Monterey Innovation Acquisition Corp.
 Monterey Innovation Acquisition Corp. Financial ConglomeratesFinance Monterey Innovation Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2020 and is headquartered in New York, NY. | Finance |
| Stemguard Therapeutics, Inc. |
